Spondyloarthropathies News

SAN DIEGO — COVID-19 vaccine boosters led to a significantly increased antibody response in patients using abatacept or TNF inhibitors regardless of whether they held medication, according to data presented at ACR Convergence 2023.

Following HHS’ blockbuster announcement of the first 10 drugs that would be subject to Medicare price negotiations, patients and providers alike have been looking forward to meaningful reductions in their costly treatments.

People who work lower-paid, manual-labor jobs are more likely to discontinue employment in the first 5 years after an early inflammatory arthritis diagnosis, vs. those who work in managerial or professional capacities, according to data.

A rheumatologist’s decision to ask about tobacco use may potentially be the leading factor in whether a patient with ankylosing spondylitis quits smoking, according to data published in Cureus.

Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.

SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.

SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to data presented at ACR Convergence 2023.

SAN DIEGO — Biologic-naïve patients with radiographic axial spondylarthritis who receive ixekizumab for 16 weeks demonstrate reduced erosion scores and increased backfill scores, according to data presented at ACR Convergence 2023.

SAN DIEGO — Compared with Medicaid and private insurance, Medicare has lagged significantly in adopting infliximab biosimilars despite the multiple options now available, according to data presented at ACR Convergence 2023.

Key details expressing arthralgia duration, morning stiffness or joint examination findings are often missing from rheumatology referral letters for inflammatory arthritis, according to data published in Rheumatology Advances in Practice.